EML4 and non-small cell lung carcinoma: For example, despite the fact that the NSCLC cell lines H3122 and H2228 harbor EML4-ALK, the antiproliferative efficacy of the ALK inhibitor TAE684 or crizotinib and ALK siRNA was insufficient against H2228 cells29,30.